TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28347608
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine delivered as sprays (MAD group)
Study: 28347608
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine delivered as drops (syringe group)
Study: 17323429
Drug: Topography-guided customized
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topography-guided customized aspheric treatment zone (CATz) ablation
Study: 15310345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled medical air and titrated intravenous midazolam
Study: 15310345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Study: 15310345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled mixture of sevoflurane 0.3% and nitrous oxide 40% in oxygen with titrated intravenous midazolam
Study: 12796591
Drug: Daily schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily schedule of topotecan (1.5 mg/m2 daily for 5 days every 3 weeks)
Study: 12796591
Drug: Continuous-infusion schedule
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion schedule of topotecan (1.3 mg/m2 per day over 72 hours every 4 weeks)
Study: 10479878
Drug: Usnic acid
Normalized name: Usnic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally before and after RS (n = 25)
Study: 10479878
Drug: Usnic acid
Normalized name: Usnic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally after RS (n = 25)
Study: 10479878
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no therapy after RS) (n = 50)
Study: 10479878
Drug: Usnic acid
Normalized name: Usnic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally (both before and after RS)
Study: 8753634
Drug: Concurrent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent group (n = 456)
Study: 8753634
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (ED, concurrent, preprogram control)
Study: 1888047
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with 0.1 mEq sodium bicarbonate added to each 20 ml (n = 30)
Study: 4003494
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 1%
Study: 26037728
Drug: Lactoferrin 250
Normalized name: lactoferrin 250 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin 250 mg capsules once daily for eight consecutive weeks
Study: 26037728
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate 150 mg capsules once daily for eight consecutive weeks
Study: 25078310
Drug: Alemtuzumab-based treatment
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab-based treatment (alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids)
Study: 25078310
Drug: Basiliximab-based treatment
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab-based treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone)
Study: 25078310
Drug: Alemtuzumab-based treatment
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab-based treatment
Study: 25078310
Drug: Basiliximab-based treatment
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab-based treatment
Study: 19933534
Drug: Perioperative steroid
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative steroid therapy
Study: 22832429
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 8 weeks
Study: 30506623
Drug: Tacrolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (3 formulations, each for two 1-week periods)
Study: 26892001
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) coupled with Virtual Reality Exposure Therapy (VRET)
Study: 22395336
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg twice a day)
Study: 11880018
Drug: Rapid induction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid induction with 2.0 mg/kg propofol followed by P5
Study: 2509250
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A)
Study: 2509250
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM injection every 4 weeks for 12 weeks (group B)
Study: 2509250
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A) in patients with large uteri
Study: 2509250
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM injection every 4 weeks for 12 weeks (group B) in patients with large uteri
Study: 28720281
Drug: H9N2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H9N2 vaccine with AS03 adjuvant (1.9µgHA+AS03A, 1.9µgHA+AS03B, 3.75µgHA+AS03A, 3.75µgHA+AS03B)
Study: 28720281
Drug: H9N2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H9N2 vaccine without adjuvant (15µg HA)
Study: 28720281
Drug: H9N2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H9N2 vaccine (any formulation) administered a third dose on day 182
Study: 25673443
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii Hook F (TwHF) 20 mg, 3 times a day for 8 weeks
Study: 25673443
Drug: Acitretin 30
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 30 mg, once a day for 8 weeks
Study: 3318436
Drug: Nabumetone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1,000 mg taken at bedtime)
Study: 31900091
Drug: Isotonic exercises
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic exercises and relaxing techniques, performed twice a week for one month.
Study: 28974425
Drug: Liposomal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal spray (n=28)
Study: 28974425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MG dropout)
Study: 17394002
Drug: Household common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household common salt solution (10 g NaCl in 1 l tap water)
Study: 11952881
Drug: Multiple Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple Insulin Injection (MI) therapy for 9 weeks
Study: 11952881
Drug: Bedtime Insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime Insulin (BTI)
Study: 2694492
Drug: Tensilon (edrophonium)
Normalized name: edrophonium chloride Injectable Solution [Tensilon]
DrugBank: Edrophonium (DB01010)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tensilon (edrophonium) administered at 2 hours
Study: 2694492
Drug: Philippine cobra
Normalized name: Viola philippica whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Philippine cobra antivenom (20, 50 or 100 ml) administered by constant intravenous infusion over 30 min
Study: 412611
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (prior inhalation)
Study: 31961936
Drug: Intermittent enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent enteral feedings 5 times daily at 4-hour intervals
Study: 31961936
Drug: Intermittent enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent enteral feedings 10 times daily at 2-hour intervals
Study: 28602319
Drug: OMS302 (Omidria
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS302 (Omidria [phenylephrine and ketorolac injection 1.0%/0.3%])
Study: 28602319
Drug: Vehicle (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (balanced salt solution)
Study: 19828955
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (4 g) + topical mesalazine enema (1 g)
Study: 19828955
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (4 g) alone
Study: 17006600
Drug: L-methionine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine (active treatment)
Study: 2557304
Drug: TRT (Thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT (Thoracic Radiation Therapy)
Study: 31781699
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants with provisional resin fixed partial denture
Study: 31781699
Drug: Conventionally loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally loaded implants according to the one-stage unloaded protocol
Study: 25966791
Drug: Balugrastim 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balugrastim 30 mg
Study: 24485296
Drug: Balugrastim 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balugrastim 40 mg
Study: 25966791
Drug: Balugrastim 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balugrastim 50 mg
Study: 15333415
Drug: oxycodone/acetaminophen 10/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone/acetaminophen 10/650 mg
Study: 11117368
Drug: RS‐127445 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS‐127445 (500 mg)
Study: 9122731
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha (rIFN‐alpha) as a single agent
Study: 9122731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rIFN‐alpha with recombinant interleukin‐2 (rIL‐2)
Study: 9122731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rIFN‐alpha with combination chemotherapy regimens
Study: 9122731
Drug: Chemoimmunotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy using dual biologic agents
Study: 26156797
Drug: LNS (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNS (140 g/d)
Study: 21674263
Drug: New formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulations of ziprasidone (inclusion complex with cyclodextrin, nano-suspension, semi-ordered HCl in polymer matrix)
Study: 21674263
Drug: New formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulations of ziprasidone
Study: 21674263
Drug: Commercial capsules
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsules (Geodon®) dosed in the fed state
Study: 18551084
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-estradiol and 2 mg drospirenone (DRSP)
Study: 19479398
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with paclitaxel (200 mg/m²) and carboplatin (AUC 6) for 3 cycles (q21)
Study: 19479398
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with paclitaxel and carboplatin
Study: 8245523
Drug: 12.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 micrograms of rgp160-mam vaccine
Study: 8245523
Drug: 50.0 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.0 micrograms of rgp160-mam vaccine
Study: 8245523
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of rgp160-mam vaccine (boosted at 18 months)
Study: 30142768
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and IVF‐ET combined treatment group
Study: 30142768
Drug: IVF‐ET single
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF‐ET single treatment group
Study: 23057533
Drug: Injection lipolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection lipolysis and hyaluronic acid dermal filler
Study: 23057533
Drug: Injection lipolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection lipolysis and hyaluronic acid dermal filler + non-ablative 1540 fractional laser
Study: 21411505
Drug: Ginseng root
Normalized name: ginseng root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng root extract (8 g/day)
Study: 21411505
Drug: Ginsenoside Re
Normalized name: Ginsenoside Re
DrugBank: Ginsenoside B2 (DB14815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside Re (250‐500 mg/day)
Study: 12813332
Drug: UFH-IPC (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH-IPC (unfractionated heparin plus intermittent pneumatic compression)
Study: 9359537
Drug: Atorvastatin (aggressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (aggressive lipid-lowering therapy)
Study: 1731548
Drug: Rapid administration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid administration of midazolam (0.1 mg/kg IV over 15 s)
Study: 1731548
Drug: Slow administration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow administration of midazolam (0.1 mg/kg IV over 5 min)
Study: 6608846
Drug: Amiodarone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (1500 mg/24 hours IV + 200 mg orally every 8th hour for 3 days, then 200 mg orally 3 times daily)
Study: 6608846
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg every 6th hour)
Study: 26471807
Drug: i-gel airway
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel airway (IGA)
Study: 17343554
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at a dosage of 0.25 mg/kg
Study: 16623024
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera cream applied 30 minutes before, immediately after, or both before and after UV exposure
Study: 7426527
Drug: Omnopon by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnopon by intramuscular injection for 24 hours after operation
Study: 7426527
Drug: Salbutamol by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol by intravenous infusion
Study: 9226208
Drug: Liothyronine (L-T3)
Normalized name: L-T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (L-T3)
Study: 31271045
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy with adjustment of the challenge-skill balance
Study: 26233871
Drug: Onion peel
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion peel extract (OPE) 100mg quercetin/d, 50mg quercetin twice daily; n=36 participants
Study: 19143950
Drug: 2 mcg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mcg.kg(‐1) IV fentanyl
Study: 19143950
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel applied over the cornea of the operative eye
Study: 18342502
Drug: Intensive acute
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation
Study: 15386806
Drug: Rosiglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone plus insulin (insulin + RSG group)
Study: 15386806
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin alone (insulin group)
Study: 16943394
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg twice daily
Study: 414266
Drug: Imipramine -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine - 25 mg t.d.s.
Study: 414266
Drug: Viloxazine -
Normalized name: viloxazine
DrugBank: Viloxazine (DB09185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viloxazine - 50 mg t.d.s.
Study: 414266
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - no tablets
Study: 31742891
Drug: Lower BP
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower BP treatment targets (not specifically defined)
Study: 23153515
Drug: Multifaceted ergonomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted ergonomic intervention program (8-week duration including ergonomic training, daily exercise program, equipment modification, computer workstation assessment, typing training)
Study: 16556618
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements (beta carotene and vitamins C and E)
Study: 11007223
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenously over 20 min, followed by 100 mg over the next 40 min)
Study: 8788536
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg, equivalent to 2-3 cups of coffee)
Study: 1632541
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose infusion of 0.125% bupivacaine at 6 mL/h after a 3-in-1 nerve block with 30 mL of 0.25% bupivacaine
Study: 1632541
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional intramuscularly administered narcotics)
Study: 22974129
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OMT) only
Study: 25427182
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with adjunctive laser therapy (5W), n=28
Study: 16036208
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (0.7 g/kg for males and 0.6 g/kg for females)
Study: 9160036
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (S)
Study: 30099096
Drug: Daily nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nitrate supplementation (70 mL beetroot juice, n = 20)
Study: 30099096
Drug: Placebo (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (70 mL nitrate-depleted beetroot juice, n = 20)
Study: 16631281
Drug: None (no-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: None (no-treatment control group)
Study: 12727080
Drug: Azithromycin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 4.5 g total for 3 weeks (1 x 500 mg weekly for 3 days)
Study: 12420857
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.i.d. for 15 days
Study: 1978480
Drug: Remoxipride 50
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 50 mg single dose
Study: 1978480
Drug: Remoxipride 50
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 50 mg, 100 mg, and 200 mg twice daily
Study: 349155
Drug: Rubidium chloride;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubidium chloride; dosage not specified; duration not specified
Study: 25807814
Drug: Syndrome Differentiated
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syndrome Differentiated Chinese Medicine Therapy
Study: 11673752
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/d
Study: 21834863
Drug: Screw-retained implant-supported
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screw-retained implant-supported full-arch casted titanium-resin prostheses
Study: 10759235
Drug: IFN‐alpha2b, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2b, 5 MU daily plus ribavirin
Study: 1569815
Drug: 13‐RED regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐RED regimen (twice weekly rifampicin 600 mg, daily ethionamide 500 mg, dapsone 100 mg)
Study: 1569815
Drug: Reduced dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced dosage of ethionamide to 5 mg/k bodyweight in the RED group
Study: 1569815
Drug: REC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: REC regimen (clofazimine 100 mg)
Study: 6339294
Drug: halometasone/triclosan cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: halometasone/triclosan cream
Study: 6339294
Drug: fluocinolone acetonide/neomycin
Normalized name: Fluocinolone Acetonide/Neomycin Sulfate 0.025%-0.5% Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluocinolone acetonide/neomycin cream